v3.26.3
Material Agreements (Details) - USD ($)
$ / shares in Units, $ in Thousands
 2 Months Ended 3 Months Ended 9 Months Ended 71 Months Ended
Aug. 17, 2026
Mar. 03, 2026
Aug. 13, 2025
Mar. 27, 2023
Mar. 02, 2023
Oct. 26, 2022
Sep. 26, 2022
Nov. 03, 2020
Oct. 23, 2020
May 21, 2020
Dec. 31, 2020
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
May 12, 2026
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Warrants issued (in shares)   375,000                                
Sale of stock, shares committed, aggregate amount   $ 5,000                                
Sale of stock, share commitment, period following effective date (in days)   90 days                                
Revenues                       $ 7,557 $ 12,807 $ 35,822 $ 31,530      
Assertio Holdings, Inc                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenues           $ 6,000                        
Proceeds from collaborators           $ 9,000                        
License and royalty revenue                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenues                       824 $ 1,038 $ 7,545 $ 2,667      
Minimum                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Warrant exercise price (in dollars per share)   $ 4.00                                
Commercial exploitation agreement with Indivior                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
License agreement term (in years)                           7 years        
Automatic renewal period of agreement (in years)         1 year                 1 year        
Notice of renewal prior to expiration (in years)         12 months                          
Additional renewal period of agreement (in years) 1 year                                  
License agreement with Sunovion Pharmaceuticals, Inc milestones                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Aggregate payment                 $ 17,000                  
License agreement with Sunovion Pharmaceuticals, Inc milestones | License and royalty revenue                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenues                   $ 4,000                
License agreement with Sunovion Pharmaceuticals, Inc.                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Aggregate payment                 22,000                  
License agreement with Sunovion Pharmaceuticals, Inc. upfront                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Aggregate payment                 $ 5,000                  
MAM Pangolin Royalty , LLC | Maximum                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Proceeds from sale of future revenue               $ 125,000                    
Zevra And Commave Therapeutics Agreement | License and royalty revenue                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenues                           $ 5,000        
Purchase And Sale Agreement | RTW Investments LP                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Exchange for the purchaser’s payment     $ 75                              
Revenue sharing percentage     9.50%                              
Revenue share payments year ten     $ 187,500                              
Revenue share payments thereafter     $ 225                              
Capitalized legal fees                       $ 760   $ 760   $ 760   $ 700
Purchase And Sale Agreement | RTW Investments LP | Minimum                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenue sharing percentage     1.00%                              
Purchase And Sale Agreement | RTW Investments LP | Maximum                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenue sharing percentage     7.50%                              
Monetization Agreement | MAM Pangolin Royalty , LLC                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Proceeds from sale of future revenue               40,000     $ 10,000         $ 50,000    
Additional proceeds from sale of future revenue               10,000                    
Proceeds from debt, contingent on additional milestones               $ 75,000                    
License & Supply Agreement | Atnahs Pharma UK Limited                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Proceeds from sale of future revenue             $ 3,500                      
License & Supply Agreement | Atnahs Pharma UK Limited, Amended Agreement                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Proceeds from sale of future revenue       $ 2,000                            
Senior Notes | Purchase And Sale Agreement | RTW Investments LP                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Interest rate (as a percent)     13.50%                              
Oaktree Capital Management LP | Line of Credit                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Credit facility, maximum borrowing capacity                                 $ 150  
Oaktree Capital Management LP | Line of Credit | Tranche A Warrant                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Warrants issued (in shares)                                 230,271  
Warrant exercise price (in dollars per share)                                 $ 4.18  
Oaktree Capital Management LP | Line of Credit | Secured Debt                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Principal amount                                 $ 55,000  
Oaktree Capital Management LP | Line of Credit | Delayed Draw Term Loan (DDTL)                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Potential increase in available borrowing capacity upon pre determined achievement of milestones                                 $ 95